Wuxi Biocity 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  SC0062 / Wuxi Biocity
    SC0062, a New Selective Endothelin Receptor Type A Antagonist in IgA Nephropathy (Room 6C, Convention Center) -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4655;    
    P2
    No abstract available In patients with IgA nephropathy and significant proteinuria, the novel ETA selective antagonist SC0062 showed a clinically meaningful reduction in proteinuria and a favorable safety profile with no risk of peripheral edema.
  • ||||||||||  SC0062 / Wuxi Biocity
    Enrollment closed:  A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease (clinicaltrials.gov) -  Sep 25, 2024   
    P2,  N=255, Active, not recruiting, 
    In patients with IgA nephropathy and significant proteinuria, the novel ETA selective antagonist SC0062 showed a clinically meaningful reduction in proteinuria and a favorable safety profile with no risk of peripheral edema. Recruiting --> Active, not recruiting
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    The Mechanism Study on a Novel CD3-EGFR Bispecific Antibody Combo Improves Osimertinib-Resistant NSCLC Tumor Environment (Exhibit Hall) -  Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1590;    
    Comparatively, Mono.mac in the Tri group upregulated pathways related to antigen processing and presentation, antitumor (AT) responses, and macrophage recruitment to the tumor, while downregulating angiogenesis pathways (Ang) as demonstrated in Figure 1G. Conclusions : The additional combination of WBP3425 and Tucidnostat with BC3448 demonstrated a synergistic efficacy to Osimertinib-resistant tumors via a multidimensional reshaping of the microenvironment, potentially offering a comprehensive approach to combat NSCLC resistance.
  • ||||||||||  SC0245 / Shijiazhuang Sagacity, Wuxi Biocity
    An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC). (Hall A; Poster Bd #: 364) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3360;    
    P1/2
    Among the 9 pts who were evaluable for tumor response, one confirmed partial response (PR) was reported in a pt with ES-SCLC (progressed on prior 1 st line of etoposide + carboplatin + serplulimab treatment) treated in the 120mg QD dose cohort, and the response sustained for 32+ weeks; five pts (5/9, 55.6%) had stable disease (SD) as their best response. SC0245 exhibited favorable safety and PK characteristics when administered in combination with IRI at doses ranging from 80mg QD to 120mg BID and the regimen has demonstrated preliminary antitumor activity in ES-SCLC, supporting further evaluation of the regimen in ES-SCLC and other relevant malignancies.
  • ||||||||||  Tagrisso (osimertinib) / AstraZeneca
    A Novel Anti-EGFR/CD3 Bispecific Antibody Exhibits Potent Efficacy for Osimertinib-resistant NSCLC (405B) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_989;    
    Additionally, the total protein of H1975-OR treated with BC3448 or Panitumumab for 2 days was subsequently subjected for Sally Sue Simple Western analysis. BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a promising agent for Osimertinib-resistant NSCLC.
  • ||||||||||  BC3402 / Wuxi Biocity
    Enrollment open, Trial initiation date:  A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML (clinicaltrials.gov) -  Jul 25, 2023   
    P1,  N=13, Recruiting, 
    BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a BC3448 exhibited potent antitumor effect in vitro and in vivo and might be a promising agent for Osimertinib-resistant NSCLC. Not yet recruiting --> Recruiting | Initiation date: Feb 2023 --> Jul 2023
  • ||||||||||  SC0191 / WuXi AppTec, Shijiazhuang Sagacity
    [VIRTUAL] Preclinical evaluation of SC0191, a small molecule inhibitor of Wee1 kinase. () -  Apr 29, 2020 - Abstract #ASCO2020ASCO_3785;    
    A novel Wee1 inhibitor, SC0191, has demonstrated excellent antitumor efficacy in TP53 mutant solid cancer preclinical studies, and represents a promising clinical candidate for treating solid tumors, such as SCLC and PC. Research Funding: Sagacity